The practicalities of actually selling the controversial new Alzheimer’s drug are proving increasingly difficult for Biogen.
If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?
Planning for this week’s three-day adcom on US accelerated approvals for anti-PD-(L)1 drugs? Here’s the background info you need.
Positive surprises with Lexicon’s Zynquista and DBV’s Viaskin Peanut show that you can never entirely write biotech off.